Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study

Background Diabetes is a major risk factor for atrial fibrillation (AF). However, it remains unclear whether individual AF phenotype and related comorbidities differ between patients who have AF with and without diabetes. This study investigated the association of diabetes with AF phenotype and card...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arjola Bano, Nicolas Rodondi, Jürg H. Beer, Giorgio Moschovitis, Richard Kobza, Stefanie Aeschbacher, Oliver Baretella, Taulant Muka, Christoph Stettler, Oscar H. Franco, Giulio Conte, Christian Sticherling, Christine S. Zuern, David Conen, Michael Kühne, Stefan Osswald, Laurent Roten, Tobias Reichlin
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	atrial fibrillation cardiovascular disease cognitive impairment diabetes quality of life Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/e11bf37220f0405690ae3f560164c790
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e11bf37220f0405690ae3f560164c790
record_format	dspace
spelling	oai:doaj.org-article:e11bf37220f0405690ae3f560164c7902021-11-16T10:22:43ZAssociation of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study10.1161/JAHA.121.0218002047-9980https://doaj.org/article/e11bf37220f0405690ae3f560164c7902021-11-01T00:00:00Zhttps://www.ahajournals.org/doi/10.1161/JAHA.121.021800https://doaj.org/toc/2047-9980Background Diabetes is a major risk factor for atrial fibrillation (AF). However, it remains unclear whether individual AF phenotype and related comorbidities differ between patients who have AF with and without diabetes. This study investigated the association of diabetes with AF phenotype and cardiac and neurological comorbidities in patients with documented AF. Methods and Results Participants in the multicenter Swiss‐AF (Swiss Atrial Fibrillation) study with data on diabetes and AF phenotype were eligible. Primary outcomes were parameters of AF phenotype, including AF type, AF symptoms, and quality of life (assessed by the European Quality of Life‐5 Dimensions Questionnaire [EQ‐5D]). Secondary outcomes were cardiac (ie, history of hypertension, myocardial infarction, and heart failure) and neurological (ie, history of stroke and cognitive impairment) comorbidities. The cross‐sectional association of diabetes with these outcomes was assessed using logistic and linear regression, adjusted for age, sex, and cardiovascular risk factors. We included 2411 patients with AF (27.4% women; median age, 73.6 years). Diabetes was not associated with nonparoxysmal AF (odds ratio [OR], 1.01; 95% CI, 0.81–1.27). Patients with diabetes less often perceived AF symptoms (OR, 0.74; 95% CI, 0.59–0.92) but had worse quality of life (β=−4.54; 95% CI, −6.40 to −2.68) than those without diabetes. Patients with diabetes were more likely to have cardiac (hypertension [OR, 3.04; 95% CI, 2.19–4.22], myocardial infarction [OR, 1.55; 95% CI, 1.18–2.03], heart failure [OR, 1.99; 95% CI, 1.57–2.51]) and neurological (stroke [OR, 1.39, 95% CI, 1.03–1.87], cognitive impairment [OR, 1.75, 95% CI, 1.39–2.21]) comorbidities. Conclusions Patients who have AF with diabetes less often perceive AF symptoms but have worse quality of life and more cardiac and neurological comorbidities than those without diabetes. This raises the question of whether patients with diabetes should be systematically screened for silent AF. Registration URL: https://www.clinicaltrials.gov; Unique Identifier: NCT02105844.Arjola BanoNicolas RodondiJürg H. BeerGiorgio MoschovitisRichard KobzaStefanie AeschbacherOliver BaretellaTaulant MukaChristoph StettlerOscar H. FrancoGiulio ConteChristian SticherlingChristine S. ZuernDavid ConenMichael KühneStefan OsswaldLaurent RotenTobias ReichlinWileyarticleatrial fibrillationcardiovascular diseasecognitive impairmentdiabetesquality of lifeDiseases of the circulatory (Cardiovascular) systemRC666-701ENJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 22 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	atrial fibrillation cardiovascular disease cognitive impairment diabetes quality of life Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	atrial fibrillation cardiovascular disease cognitive impairment diabetes quality of life Diseases of the circulatory (Cardiovascular) system RC666-701 Arjola Bano Nicolas Rodondi Jürg H. Beer Giorgio Moschovitis Richard Kobza Stefanie Aeschbacher Oliver Baretella Taulant Muka Christoph Stettler Oscar H. Franco Giulio Conte Christian Sticherling Christine S. Zuern David Conen Michael Kühne Stefan Osswald Laurent Roten Tobias Reichlin Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study
description	Background Diabetes is a major risk factor for atrial fibrillation (AF). However, it remains unclear whether individual AF phenotype and related comorbidities differ between patients who have AF with and without diabetes. This study investigated the association of diabetes with AF phenotype and cardiac and neurological comorbidities in patients with documented AF. Methods and Results Participants in the multicenter Swiss‐AF (Swiss Atrial Fibrillation) study with data on diabetes and AF phenotype were eligible. Primary outcomes were parameters of AF phenotype, including AF type, AF symptoms, and quality of life (assessed by the European Quality of Life‐5 Dimensions Questionnaire [EQ‐5D]). Secondary outcomes were cardiac (ie, history of hypertension, myocardial infarction, and heart failure) and neurological (ie, history of stroke and cognitive impairment) comorbidities. The cross‐sectional association of diabetes with these outcomes was assessed using logistic and linear regression, adjusted for age, sex, and cardiovascular risk factors. We included 2411 patients with AF (27.4% women; median age, 73.6 years). Diabetes was not associated with nonparoxysmal AF (odds ratio [OR], 1.01; 95% CI, 0.81–1.27). Patients with diabetes less often perceived AF symptoms (OR, 0.74; 95% CI, 0.59–0.92) but had worse quality of life (β=−4.54; 95% CI, −6.40 to −2.68) than those without diabetes. Patients with diabetes were more likely to have cardiac (hypertension [OR, 3.04; 95% CI, 2.19–4.22], myocardial infarction [OR, 1.55; 95% CI, 1.18–2.03], heart failure [OR, 1.99; 95% CI, 1.57–2.51]) and neurological (stroke [OR, 1.39, 95% CI, 1.03–1.87], cognitive impairment [OR, 1.75, 95% CI, 1.39–2.21]) comorbidities. Conclusions Patients who have AF with diabetes less often perceive AF symptoms but have worse quality of life and more cardiac and neurological comorbidities than those without diabetes. This raises the question of whether patients with diabetes should be systematically screened for silent AF. Registration URL: https://www.clinicaltrials.gov; Unique Identifier: NCT02105844.
format	article
author	Arjola Bano Nicolas Rodondi Jürg H. Beer Giorgio Moschovitis Richard Kobza Stefanie Aeschbacher Oliver Baretella Taulant Muka Christoph Stettler Oscar H. Franco Giulio Conte Christian Sticherling Christine S. Zuern David Conen Michael Kühne Stefan Osswald Laurent Roten Tobias Reichlin
author_facet	Arjola Bano Nicolas Rodondi Jürg H. Beer Giorgio Moschovitis Richard Kobza Stefanie Aeschbacher Oliver Baretella Taulant Muka Christoph Stettler Oscar H. Franco Giulio Conte Christian Sticherling Christine S. Zuern David Conen Michael Kühne Stefan Osswald Laurent Roten Tobias Reichlin
author_sort	Arjola Bano
title	Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study
title_short	Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study
title_full	Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study
title_fullStr	Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study
title_full_unstemmed	Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study
title_sort	association of diabetes with atrial fibrillation phenotype and cardiac and neurological comorbidities: insights from the swiss‐af study
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/e11bf37220f0405690ae3f560164c790
work_keys_str_mv	AT arjolabano associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT nicolasrodondi associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT jurghbeer associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT giorgiomoschovitis associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT richardkobza associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT stefanieaeschbacher associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT oliverbaretella associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT taulantmuka associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT christophstettler associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT oscarhfranco associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT giulioconte associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT christiansticherling associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT christineszuern associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT davidconen associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT michaelkuhne associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT stefanosswald associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT laurentroten associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy AT tobiasreichlin associationofdiabeteswithatrialfibrillationphenotypeandcardiacandneurologicalcomorbiditiesinsightsfromtheswissafstudy
_version_	1718426577009639424

Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study

Ejemplares similares